Webinar: Accelerating multispecific antibody development with Opti-mAb

The Knut and Alice Wallenberg Foundation is granting SEK 900 million to thirty research projects that international experts have judged to be groundbreaking and at the forefront of global research. Ten of the projects are in medicine, spanning cancer, immunology, hearing restoration, and fibromyalgia.

The Drug Discovery and Development (DDD) platform at SciLifeLab has completed the first GMP-compatible cell line developed within BRIDGE Sweden, a national initiative to strengthen Sweden’s capacity for biologics development. The top-performing clones produce more than seven grams of monoclonal antibody per liter.

Eric Honroth is stepping down as President Life Science and member of the Executive Team at Swedish medtech company Getinge to take on an external role.

Joakim Lundeberg, Professor of Molecular Biotechnology at KTH Royal Institute of Technology, has received the 2026 Gold Medal from the Royal Swedish Academy of Engineering Sciences (IVA) for developing spatial transcriptomics, a method now used in life science research worldwide.

Danish allergy company ALK-Abelló has upgraded its full-year 2026 outlook and now expects revenue growth of 16–17% in local currencies, up from 14–16%, driven by strong tablet sales across all regions.

Eight out of twelve patients with B-cell lymphoma and no remaining curative treatment options achieved a complete metabolic response after treatment with Elicera Therapeutics’ ELC-301. The results come from the now-completed Phase I part of the Swedish CARMA study.

Gothenburg-based OnDosis has entered a strategic collaboration with Adare Pharma Solutions, a US contract development and manufacturing organization (CDMO), to advance its lead ADHD program toward the US market. The partnership gives OnDosis commercial-scale manufacturing capacity in the US.